Compare Adaptive Biotechnologies Corp (ADPT) vs Bilibili Inc (BILI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bilibili Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Bilibili Inc trades at $18.1 (market cap $7.28B). The key difference: Bilibili Inc is far larger — about 2.2× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BILI | |
|---|---|---|
Market Cap | $3.33B | $7.28B |
Sector | Health | Media |
52-Week High | $22.37 | $35.92 |
52-Week Low | $10.24 | $15.96 |
Enterprise Value | $3.19B | $5.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Bilibili (BILI) trades at $17.90, up 4.43% today, with a bullish technical signal despite mixed moving average indicators. The company reported Q1 2026 EPS of $0.19, beating expectations, and maintains strong analyst support with 83% buy ratings. Recent news highlights a new $300 million share repurchase program and continued user growth, though revenue expansion remains moderate.
The outlook is positive given earnings beats and shareholder-friendly buybacks, but risks include competitive pressures in China's video platform market and reliance on advertising growth. Upside potential hinges on margin expansion and successful AI integration, while macroeconomic volatility poses a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →
